Sugi Predict

Sugi Predict / Compounds / SCHEMBL19927751

SCHEMBL19927751

SCHEMBL19927751

C[C@@]1(C(=O)O)CCCN(c2cccc(S(=O)(=O)Nc3cccc(-c4ccccc4C4CC4)n3)n2)C1

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.37
▸ HSD11B1 P28845 2/20 0.34
▸ KIF18A Q8NI77 11/20 0.33
▸ DGAT1 O75907 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ RORC P51449 1/20 0.32
▸ RORB Q92753 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ SYK P43405 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464332 1.00 CHRNA7 (0.37) CHRNA7HSD11B1KIF18ADGAT1KCNH2
SCHEMBL19927754 1.00 CHRNA7 (0.37) CHRNA7HSD11B1KIF18ADGAT1KCNH2
SCHEMBL19951441 0.91 RORC (0.33) CHRNA7HSD11B1KIF18ADGAT1KCNH2
SCHEMBL19951440 0.91 RORC (0.33) CHRNA7HSD11B1KIF18ADGAT1KCNH2
SCHEMBL19925715 0.89 RORC (0.32) KIF18ADGAT1KCNH2CNR2RORC
SCHEMBL29464456 0.89 RORC (0.32) KIF18ADGAT1KCNH2CNR2RORC
SCHEMBL19925709 0.89 RORC (0.32) KIF18ADGAT1KCNH2CNR2RORC
SCHEMBL19951367 0.89 KIF18A (0.35) HSD11B1KIF18ADGAT1KCNH2CNR1
SCHEMBL19951369 0.89 KIF18A (0.35) HSD11B1KIF18ADGAT1KCNH2CNR1
SCHEMBL29464441 0.89 KIF18A (0.35) HSD11B1KIF18ADGAT1KCNH2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 — — CN claimed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 — — EP claimed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 — — US claimed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 — — US claimed
EP-3504194-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2019-07-03 — — EP claimed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US claimed
WO-2018042316-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2018-03-08 — — WO claimed
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 — — CN disclosed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 — — EP disclosed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 — — EP disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 — — US disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 — — US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 — — US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 — — US disclosed
EP-3504194-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2019-07-03 — — EP disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US disclosed
WO-2018042316-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2018-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 CHRNA7 1437/4885HSD11B1 3742/4885KIF18A 4084/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 CHRNA7 1437/4885HSD11B1 3742/4885KIF18A 4084/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 CHRNA7 1437/4885HSD11B1 3742/4885KIF18A 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.